Peptides: The Promising, the Premature, and the Profitable

I’d barely made it into the exam room when I got THE question. “What’s the deal with peptides? I want to be skinny, look good, and feel great like everyone else. I feel like I’m behind the eight ball.”

I hear some version of this every week (every day might be more accurate). And I understand it — the promise of optimized energy, faster recovery, a leaner body, sharper thinking is alluring. In a world where medical trends move at lightning speed, the cautious physician starts to look like the one who just hasn’t caught up. I want to be clear: I’m not behind the eight ball. And neither are you for asking.

Peptides are all the rage--it’s a word we hear and see all over the place. But the truth is, peptides are nothing new. The word “peptide” simply describes a chain of amino acids (amino acids are the building blocks of proteins) which act as cell messengers, and we have been prescribing peptide-based drugs for a century. Insulin is a peptide— like other peptides it occurs naturally in the body and is a molecule that has kept millions of diabetics alive since the 1920s. There are several other examples: Octreotide, used for carcinoid tumors. Leuprolide, a hormonal cancer therapy. And, of course, the drugs generating the most conversation in medicine right now — semaglutide, tirzepatide, the GLP-1 agonists. They were developed based on naturally occurring (or nature-adjacent) molecules.

The current generation of wellness peptides — BPC-157, TB-500, CJC-1295, ipamorelin, among others — follows exactly this logic. The science is genuinely interesting. BPC-157, in particular, shows real activity in tissue repair and angiogenesis (the formation of new blood vessels) in preclinical research.

Here’s what makes academic clinicians uneasy. The research base for most wellness peptides consists almost entirely of animal models — predominantly rodent studies — with a disproportionate share of the work coming from a single research group. That’s already a methodological flag. Beyond that, we have no controlled human trials establishing therapeutic dosing, no data on adverse event rates across different populations, and no consensus on what monitoring a patient on these compounds should require.

Without that data, we are genuinely flying blind on individual risk. The woman asking me about peptides for weight loss is physiologically very different than a rat. Her personal history also matters. A prior malignancy. An autoimmune condition. A clotting disorder. Peptides that stimulate blood vessel growth could have truly catastrophic consequences in those contexts. What can and what does happen when people are given these drugs? We don’t know, because we haven’t studied it. And that unknowing is not a minor technicality. It is the entire point.

On social media, BPC-157 has earned a sexy nickname: the “Wolverine peptide,” after the comic-book mutant whose claim to fame is healing from virtually anything in minutes. It’s a clever bit of branding — who wouldn’t want that? But here’s the gap between the myth and the medicine: BPC-157’s tissue-repair signaling is real, interesting biology — but it’s been tested almost exclusively in rats, by one lab, for one set of outcomes. The leap from “promising rodent data” to “human superhero serum” is exactly the leap your Instagram feed wants you to make without noticing you made it.

You may have seen headlines recently about the FDA “clearing” peptides, or saw somewhere that BPC-157 is now legal. Here is what actually happened: in April 2026, the FDA removed BPC-157 and eleven other peptides from its Category 2 list — a DO NOT compound list of substances flagged for significant safety concerns. But removal from the Category 2 list is not a green light. Those peptides are now in a gray zone: neither explicitly blocked nor authorized. An FDA advisory committee is scheduled to review them in July 2026. For now, they remain unapproved for any human indication. “Available” and “approved” are unfortunately not the same thing. And it leaves many of us confused — are these okay to take or not?

If you’re looking to state medical boards for clarity, you may be sorely disappointed. Regulations on prescribing peptides vary widely by state. Louisiana recently passed a law (SB 253) that makes it much easier to prescribe compounded peptides (effective August 1, 2026) without risking legal repercussions, but that’s not the case in our neighboring state, Alabama. On May 26th, Alabama’s Board of Medical Examiners issued an unambiguous warning to physicians: do not prescribe, dispense, administer, or recommend non-FDA-approved research-grade peptides under any circumstances. The board was explicit that a patient consent form or waiver does not protect the provider; the prohibition stands regardless.

I am not categorically opposed to patients pursuing peptides when conventional medicine has run out of answers — a refractory neurodegenerative disease, a traumatic brain injury, a cancer with no remaining standard-of-care options. In those contexts, the risk-benefit math changes. The calculus shifts when the alternative is watching someone decline without intervention. Even then, I'd want a clear rationale, a specialist's documented oversight, and explicit, honest informed consent — not vials ordered off a website on the strength of a promise.

I want the absolute best for my patients. When it comes to a medication we put into our bodies, we must have high standards and a solid knowledge base to work with, at least regarding the basic risks in humans and the line between benefit and harm. As a board-certified, licensed physician, I cannot recommend these compounds for wellness, weight management, or aesthetics in otherwise healthy women, where the risks are speculative but real, and the benefits are unquantified. That is not caution for its own sake. That is the standard I hold for every drug I prescribe.

The peptide era in medicine is coming. I believe that. But we are not there yet — and the distance between promising and proven is exactly where patients get hurt.

Dr. Kate Freeman is a board-certified family medicine physician and menopause specialist, and the founder of Femme Executive Health, a concierge practice in Baton Rouge serving high-achieving women with hormone support, comprehensive primary care, and executive physicals built for women who don’t have time to be unwell. She believes good medicine should be both rigorous and humane — which is, more or less, the whole point of this newsletter.

If you’re navigating a question like the one in this piece — peptides, hormones, or just the sense that something’s off and no one’s taking the time to figure out why — schedule a visit at femmehealth.net. Let’s talk it through.